ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Tenecteplase

Also written as “tenecteplase”, “rhTNK-tPA” and “GNR-060”.

Its studies are mostly in Myocardial Infarction · Ischemic Stroke · ST Elevation Myocardial Infarction · Stroke · Heart Arrest, led by 4 companies.

Drug pageTenecteplase: every studyAll 98 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Sep 9, 200516 company-led studies, 2 open or runningNext primary completion: Sep 30, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Boehringer Ingelheimits history only81 open or runningphase 4since Sep 9, 2005Sep 7, 2005Oct 2, 2027phase 3 · NCT07361302
Hoffmann-La Rocheits history only50 open or runningphase 3since Nov 2, 2006Nov 2, 2006none ahead
CSPC Pharmaceutical Group21 open or runningphase 4since Jun 12, 2016Jun 12, 2016Sep 30, 2027phase 3 · NCT07201688
AO GENERIUMits history only10 open or runningphase 3since Oct 26, 2022Oct 26, 2022none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of CSPC Pharmaceutical Group only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 12, 2016First study: phase 4 study in Acute ST Elevation Myocardial InfarctionFirst studyNCT02835534 · 818 enrolled · China
  2. Sep 22, 2025Phase 3 study in Ischemic StrokeNCT07201688 · 890 planned · China

Ahead

  1. Sep 30, 2027Primary completion: phase 3 study in Ischemic StrokeNCT07201688

TargetBeta

PLAT →read by rule
“Tissue-type plasminogen activator exogenous protein”ChEMBL 37, by rule

Studies

All 2 CSPC Pharmaceutical Group leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07201688Ischemic Stroke · China3RecruitingSep 30, 2027890
NCT02835534Acute ST Elevation Myocardial Infarction · China4CompletedOct 2019818

How it is read

Names in the registry

  • “tenecteplase”, 6 entries
  • “Tenecteplase”, 5 entries
  • “rhTNK-tPA”, 2 entries
  • “GNR-060”, 1 entry
  • “Full dose TNK-tPA”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.